Conference Information

Welcome

Pulsus Group welcomes you all on its new event, World Congress on Bio Markers to be held as Webinar, on June 4-5, 2021. It features a keynote presentation, innovators, academicians from across cancer sites.

The basis of biomarkers 2021 is together prominent personalities and professionals from the field of pharmacy, medicine, and research who share similar interests and ideologies in relation to particularly common diseases in the oncology department. Biomarkers 2021 are intended to bring information about new advanced methodologies in the technologies used in biomarkers with the applications of Nanotech to curb nightmarish diseases such as cancer.

The conference will offer a broad platform to share vital and up-to-date innovations in the field of biomarkers, immunology, biotechnology, pharmacology, neurology, microbiology.

Biomarkers 2021 is a two-day scientific event, business meeting, fair and trade as Webinar. Biomarkers 2021 bring an opportunity to discuss and learn about advances in biomarker research on access together with unique and international experts, scientists and decision-makers from both academia and industry around the globe to exchange knowledge, innovations, and research and expertise in the field of cancer treatments.

Why to attend???

Biomarkers 2021 brings together experts from all aspects to meet and discuss the future of clinical research and the importance of biomarkers in today’s world to survive with better health. This conference discusses technological developments, new discoveries, and recent trends in biomarkers. There will be lectures, interactions, discussions, keynote addresses, poster presentations, etc. This conference gives you a chance to learn more about biomarkers.

Targeted Audience:

Cancer researchers
Biomarkers associations
Scientists
Clinical research organizations
Biomarkers research scientists
Student
Oncologist
Biotechnology professionals
Biochemist
Cell biologist
Radiologist
Pathologist
Pharmaceuticals companies
Medical companies
Genetic researchers
Immunologist
Bioengineers

Scientific Sessions

Session 1: Biomarkers

A biomarker is an indicator that can be accurately measured as a signal for normal biological function, pathogenic pathways, or drug response to therapeutic drug mediation. Biological markers are usually molecularly shaped. Biological markers occur in various bodily functions, including diagnosis and prognosis of disease, prediction and calculation of treatment response, and safety assessment. These biomarkers are developed and approved for use in drug development, and to support the approval of drug products.

Predisposition Biomarkers
Diagnostic Biomarkers
Prognostic Biomarkers
Predictive Biomarkers

Session 2: Biomarkers in oncology

The biomarkers used to treat cancer are referred to as cancer biomarkers. They are helpful in making specific diagnoses. Cancer biomarkers also identify and determine whether tumors are of primary or metastatic origin. A biomarker for cancer can be a molecule secreted by a tumor or a specific body response to the presence of cancer. Biomarkers of human prostate, breast, ovarian and lung cancers, as well as those of heart disease, arthritis, asthma and cystic fibrosis, have been examined. Biological markers can determine the accuracy of the diagnosis, can be linked to other investigations to suspect the type of cancer.

Tumor markers in cancer care
Role of biomarkers in cancer vaccines developments
Cell proliferation biomarkers
Evaluation of biomarkers in clinical trails

Session 3: Clinical and translational biomarkers

Detection stages of clinical support and translated biomarkers are used to identify the effect of compound on organs or tissues before the clinical effect is demonstrated. It can be classified into three general classes: biomarkers for disease, target biomarkers and Mechanism biomarkers. A biomarker for translation is based on whether it can be noticeable, measurable and ultimately it can be qualified or verified.

Biomarkers in clinical trails, designs
Biomarkers in strategies and application case studies
Applications of biomarkers in drug discovery

Session 4: Cardiovascular Biomarkers

Cardiovascular disease (CVD) remains the leading factor in the world. The identification of traditional risk factors such as age, hypertension, diabetes and smoking improved the primary prevention of CVD. Heart markers are measured biomarkers to evaluate heart function. They are often discussed in the context of myocardial infarction, but other conditions can lead to an increase in the level of the heart marker. Cardiac biomarkers are elements that release into the blood when the heart is injured or strained. A heart marker is used to identify and stratify proliferation of patients with chest pain and suspected acute coronary syndrome (ACS). These markers include enzymes, hormones and proteins. Cardiac biomarkers have emerged as an essential tool in cardiology over the past fifty years, namely for primary and secondary prevention, diagnosis and treatment of acute myocardial infarction (AMI), and diagnosis and stratification of the risk of heart failure.

Circulatory biomarkers
Biomarkers for heart failures
Biomarkers for acute coronary syndrome
Biomarkers for metabolic syndrome

Session 5: Molecular Biomarkers

Molecular biomarkers defined as biomarkers that can be discovered through basic and widely accepted platforms such as genomics and proteomics. Apart from genomics and proteomics platforms, biomarker analysis techniques such as metabolomics, lipidomic, glycaemic are most commonly used as biomarker detection techniques. Molecular biomarkers are classified into pathological biomarkers, nucleic acid biomarkers, insilco biomarkers, glycoprotein biomarkers and bio-imaging markers based on their structure and function. These biomarkers can be tested for non-abnormally collected biological fluids, such as blood or serum.

Nucleic acid- based markers
Lipid biomarkers
Proteomic biomarkers
Genomic biomarkers
Micro RNA biomarkers

Session 6: Biomarkers in drug Discovery

Drug Discovery with biomarkers is used exclusively for diagnosis and monitoring of patients in clinical trials. Biological markers improve the success rates of drug development programs and thus accelerate the availability of advanced therapies. Biomarker development is a multi-step and repetitive process starting with the discovery of biomarkers in infectious diseases. In this session, an analytical validation phase of biomarker development, pharmacogenomics, functional proteomics, biological analytical validation method, pharmacokinetic models will be developed.

Biomarkers in Drug formulation
Biomarkers in drug design
Evaluation of dose response
Biomarkers of toxicity and pharmacology

Session 7: Applications in Biomarkers

Bio markers are used as diagnostic tools for accurately identifying disease states, for identifying high-risk and predictable individuals, effectively treating patients with illnesses, and are also targeted to specific biological sites. Advances in genomics, proteomics, metabolomics and bioinformatics have made it possible to discover several biomarkers.

Burden of disease biomarkers
Investigative
Prognostic
Diagnostic

Session 8: Blood Biomarker

Blood biomarkers are involved in multiple sclerosis (MS) studies, autoimmune dysfunction of the central nervous system. There is a significant need not met by biomarkers to assess prognosis, response to treatment or potential complications in treatment. There are several limitations in the process of detecting and validating a good biomarker, such as the pathophysiological complexity of multiple sclerosis and the technical difficulties of a global standard of methods for sampling, processing, and retaining biological samples.

Biomarkers as decision making in clinical practice
Biomarkers as Alzheimer’s diseases
Biomarkers for PTSD (Post Traumatic Stress Disorder)

Session 9: Biomarkers in Pharmacology

Biological markers are major tools in drug development and drug research. Biological markers have been recognized for making the drug development process more efficient and becoming an essential part of pharmacology and drug research. Several biomarkers are expected to eventually be transferred to the clinical laboratory. Biological markers demonstrate drug-dose-response relationships between changes in biomarker, onset of injury, and severity of injury consistent with the progression of the injury.

Clinical trials on Biomarkers pharmacology
Prediction in pharmacology
Drug development in Pharmacology

Session 10: Genomics and proteomics

Genomics-related biomarkers measure changes in the amount or nature of nucleic acids. DNA-based biomarkers include copy number variation, mutations and epigenetic modification. Biological markers based on RNA expression include quantification of mRNA, microRNA and long non-coding RNA expression. The serum consists of several small size peptides, as a result of various cellular activities, called a serum proteome. Proteomics is widely used in the study of a wide range of medical fields including drug development and biomarker discovery. By coordinating with other advanced genomics and bioinformatics techniques, proteomics has the broad contribution to identifying biomarkers and revolutionizing the drug development process.

Technologies of proteomics and genomics
Structural and functional genomics

Session 11: Biomarker in neuro- oncology

Neurology deals with the diagnosis and treatment of central and peripheral nervous system disease and is one of the typical disciplines in which personalized medicine has become an important part of clinical trials. Various issues in neurology regarding personalized medicine and diagnostic, prognostic and predictive biomarkers should be discussed. The role of biomarkers and personalized medicine in neuro-oncology is becoming extremely important. The actual state of knowledge should be discussed in several areas of neurology.

Cerebrospinal fluid biomarkers
Biomarkers for heart failures
Biomarkers for early identification of neurological disorders

Session 12: Advancements in Biomarkers

The use of biomarkers and diagnostic assessments continues to evolve with more uses and the introduction of more effective sensitivity tests. These tests are powerful clinical care tools that approach different therapeutic areas such as oncology, immunology, cardiology and endocrinology. Recent advances in biosensors to detect biomarkers in cancer treatment.

Biomarkers for Parkinson’s diseases
Gene array in addition to proteomic technologies
Urine- based biomarkers as bladder tumor antigen, nuclear matrix protein-22

Session 13: Biomarker in health and disorder

Biomarkers in health and disorders are concerned about the promising findings in a pediatric autism spectrum disorder survey. The researchers were able to use cerebral magnetic resonance imaging (MRI) to assess cortical and cerebrovascular development, in infants aged 6-12 months at risk of ASD with ASD affected children, who will have ASD up to 24 months. While this study requires further validation in a larger group of 15 out of 106 high-risk subjects who eventually developed ASD, it does talk about the enormous and unmet medical need of biomarkers for neural and psychiatric disorders. Co-morbidity with other psychiatric disorders is also uncommon and contributes to dizzying heterogeneity in possible diagnoses. Clinical biomarkers can help transcend these limitations.

Indication for presence or absence of underlying disease states
LDL cholesterol
Blood pressure
Heart rate variability
Vital capacity

Session 14: Biomarkers for Noncancerous diseases

Bio markers play an important role in the prognosis and diagnosis of various cardiovascular and neurological diseases. Diseases that are deadly from age have possible treatment and easy diagnosis with advances in biomarkers using various diagnostic methods and imaging technologies. Cardiac biomarkers and neuro-biomarkers have revolutionized disease diagnosis and prognosis. These biomarkers are also used in many other non-cancerous diseases. Some of the important ones are Alzheimer's disease, cardiovascular disease, Huntington's disease, degenerative disease, diabetes.

Risk assessment
Prognosis and treatment prediction
Monitoring treatment response

Session 15: Imaging Biomarkers

Bio-imaging markers are the class of biomarkers that allow earlier detection of disease compared to molecular biomarkers, which optimizes the translational research in drug discovery and researchers under cancer images in the market. Some of the image-based biomarkers are X-ray, computed tomography (CT), positron emission tomography (PET), single emission computed tomography (SPECT), and magnetic resonance imaging (MRI).

Imaging in Neuroscience
Imaging in biomarkers in musculoskeletal system
Imaging internal tissues and organs
Imaging in clinical translation

Session 16: Digital Biomarkers

Digital biomarkers are commonly referred to as a digital device diagnosis that can provide clinical information as significant digital data. It can predict the physiological and behavioural studies of the patient's condition which determine what a healthy normal stage of disease and future health outcomes. It can be called a self-diagnostic device that can be wearable, portable, transplantable and digestible depending on diagnosis and condition.

E- textiles in medicines
Diagnosis of medical devices
Mobile health technologies

Session 17: Biomarkers Testing

Biological or genetic tests are a set of tests that look for the molecular signs of health so that doctors can best treat them. Biological markers, a basis for accurate oncology, are very important in the management of oesophageal, breast and lung cancers. Testing practices are intensively assessed, affecting the quality of diagnosis and affecting pathologists, oncologists and patients. Advances in biomarker testing are primarily in the fields of cancer that have been divided into chromosomes, gene tests and biochemical tests. Micro-RNA biomarkers, number of other clinical biomarkers that have emerged in the latest study have opened the way for wider biomarker testing.

Fusion protein testing
Chromosome test
Biochemical test
Gene test

Session 18: Diagnostics and therapeutic Biomarkers

Biomarkers are used to detect the presence of a disease or condition and to detect individuals with a subtype of disease. Diagnostic biomarkers allow the development of specific cancer screening programs (cellular and molecular pathology). Therapeutic biomarkers deal with a huge variety of therapeutic treatments for cardiovascular disease, rarity, infectious disease, hereditary disease.

Biomarkers for personalized immunotherapies
Biomarkers for cancer therapy such as Endometrial cancer, Ovarian cancer, lung cancer etc.
Emerging biomarkers for diseases like Autoimmune diseases, renal damage, cardiovascular damages etc.

Market Analysis

Market Analysis:

Growth in the biomarker market is due to factors such as increasing the use of diagnostic biomarkers, R&D in the pharmaceutical and biotechnology fields, the high amount of cancer, new innovations in biomarker research and low-cost clinical trials in developing countries. High capital investment and low-cost ratio and technical storage issues are the major factors limiting the growth of this market.

The global biomarkers market has increased demand in recent years due to rapid population growth, rapid growth in IT industry leading to increased efforts towards drug discovery. The entry of new office holders is expected to further stimulate market growth. The advances and innovations of biomarkers in the medical arena such as cancer research and treatment will drive the future growth of the global biomarkers market. Biological markers are widely used to detect diseases such as immunological disorders, neurological disorders, cancer, cardiovascular disorders and more. In the oncology arena, three recent biomarkers have been added to accepted models of breast cancer risk to identify women at higher risk of breast cancer.

The global biomarkers market was estimated at $24.10billion in 2015, $28.00 billion in 2016, $34.00 billion by 2017, $41.2 billion in 2018, USD 45.55 billion in 2020, USD 53.3 billion in 2021, $67.33 billion by 2024.

List of universities associated with Biomarkers in Worldwide:

United Arab Emirates University, UAE.
The University Of Arizona, USA.
University of Leicester, UK.
University of Skövde, Sweden.
Technical University of Munich, Germany.
The University of Sheffield, UK.
Middlesex University, UK.
UCL, UK.

List of Research centres associated with Biomarkers in Worldwide:

Centre for Biomarker Discovery & Translation, USA
Manchester Biomedical Research Centre, UK
Allergy and Clinical Immunology Research Group, Belgium
Pacific Biomarkers, USA
Eurofins, Taiwan
BRAIN, UK
ICR, UK

Analysis of biomarkers for next 5 years:

Biological markers successfully predict drug efficacy quickly from conventional clinical endpoints. These Biomarker accessories will also inflate its demand among end-user industries over the next few years. From medical oncology to nanotech sectors, biomarkers have been expanding their branches throughout the years and plan to expand the field in science and technology in the future.

Conclusion

Biological markers have a covert position in the world of medicine and health. It's the age of technology and every day is a day of innovation and new invention. Expertise increases daily in relation to our expectations and lifestyle. We can hope for better tomorrow, where we look at early detection perhaps not only for cancer but other diseases as well.

References:

https://www.globenewswire.com